This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Examining the potential of Valneva and Pfizer's Lyme disease vaccine, VLA15
Ticker(s): VALN, PFEWho's the expert?
Institution: Mass General Brigham
- Infectious disease specialist at Mass General Brigham; Trained at Beth Israel Hospital, Brigham & Women's Hospital, Dana-Farber Cancer Institute, Children's Hospital and the Veterans Administration Hospitals.
- Manages 50 patients with lyme disease.
- Specializes in travel medicine, flu, hospital acquired infections, Covid-19, and pneumonia.
Interview GoalThis conversation will focus on VLA15; a multivalent recombinant protein vaccine candidate that targets six serotypes of Borrelia currently in development by Valneva and Pfizer.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
